136010-49-6

Basic information

• Product Name: H-3-thiophen-2-yl-L-alanine amide of (2S,3R,4S)-2-amino-1-cyclohexyl-3,4-dihydroxy-6-methylheptane
• Synonyms: H-3-thiophen-2-yl-L-alanine amide of (2S,3R,4S)-2-amino-1-cyclohexyl-3,4-dihydroxy-6-methylheptane
• CAS NO: 136010-49-6
• Molecular Weight: 396.594
• Mol File: 136010-49-6.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: H-3-thiophen-2-yl-L-alanine amide of (2S,3R,4S)-2-amino-1-cyclohexyl-3,4-dihydroxy-6-methylheptane(CAS DataBase Reference)
• NIST Chemistry Reference: H-3-thiophen-2-yl-L-alanine amide of (2S,3R,4S)-2-amino-1-cyclohexyl-3,4-dihydroxy-6-methylheptane(136010-49-6)
• EPA Substance Registry System: H-3-thiophen-2-yl-L-alanine amide of (2S,3R,4S)-2-amino-1-cyclohexyl-3,4-dihydroxy-6-methylheptane(136010-49-6)

Safety Data

• Hazardous Substances Data: 136010-49-6(Hazardous Substances Data)

Upstream product

• 104882-10-2 (2S,3R,4S)-2-[(tert-butyloxycarbonyl)amino]-1-cyclohexyl-3,4-dihydroxy-6-methylheptane 
• 122621-77-6 (2S,3R,4S)-2-amino-1-cyclohexyl-3,4-dihydroxy-6-methylheptane 
• 56675-37-7 (S)-2-tert-butoxycarbonylamino-3-thiophen-2-yl-propionic acid 
• 136010-46-3 N-(tert-butoxycarbonyl)-3-thiophen-2-yl-L-alanine amide of (2S,3R,4S)-2-amino-1-cyclohexyl-3,4-dihydroxy-6-methylheptane 

Downstream Products

• 1053247-36-1 {2-[(S)-1-[(S)-1-((1S,2R,3S)-1-Cyclohexylmethyl-2,3-dihydroxy-5-methyl-hexylcarbamoyl)-2-thiophen-2-yl-ethylcarbamoyl]-2-(4-methoxy-phenyl)-ethylcarbamoyl]-1,1-dimethyl-ethyl}-carbamic acid tert-butyl ester 

Relevant articles and documents

Studies directed toward the design of orally active renin inhibitors. 1. Some factors influencing the absorption of small peptides

A systematic evaluation of structure-absorption relationships using a high throughput intraduodenal rat screening model has led to the delineation of a set of structural parameters that appear to govern bioavailability in a series of peptide-based renin inhibitors. Optimum structures, exemplified by 25 and 41, incorporated a single, solubilizing substituent at the C- or N- terminus combined with a lipophilic P2-site residue. Both inhibitors gave unprecedented plasma drug levels upon intraduodenal administration to monkeys, and the calculated bioavailability for 41 (14 ± 4%) is the highest reported for any peptidic renin inhibitor.